Creating a new medication to help people with alcohol use disorder
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
['FUNDING_OTHER'] · AFASCI, INC. · NIH-10933482
This study is testing a new medication called AFA-281 to see if it can help people with alcohol use disorder, especially those who also deal with pain, anxiety, or depression, and if it works well, it could offer a new way to support their recovery.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | AFASCI, INC. (nih funded) |
| Locations | 1 site (REDWOOD CITY, UNITED STATES) |
| Trial ID | NIH-10933482 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel medication, AFA-281, aimed at treating alcohol use disorder (AUD), which is a common condition often linked with chronic pain, anxiety, and depression. The researchers will conduct proof-of-concept studies using established rodent models to evaluate the effectiveness of AFA-281, a dual inhibitor targeting specific calcium channels and enzymes. The approach includes rigorous testing to ensure the medication is safe and effective, utilizing advanced drug design techniques and pharmacokinetic studies to assess how the drug behaves in the body. If successful, this medication could provide a new treatment option for individuals struggling with AUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcohol use disorder, particularly those who may also experience chronic pain or co-occurring mental health conditions.
Not a fit: Patients who do not have alcohol use disorder or those who are not seeking treatment for alcohol-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective medication for alcohol use disorder with fewer side effects.
How similar studies have performed: Previous research has shown promise in developing medications targeting similar pathways for treating substance use disorders, indicating potential for success in this novel approach.
Where this research is happening
REDWOOD CITY, UNITED STATES
- AFASCI, INC. — REDWOOD CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XIE, XINMIN SIMON — AFASCI, INC.
- Study coordinator: XIE, XINMIN SIMON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Affective Disorders